Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (227) clinical trials

The purpose of this study is to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 (closed) and Phase 2 (open to enrollment)

Phase N/A

The purpose of this study is to assess the safety, tolerability, and efficacy when combining INCB024360 and Nivolumab in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 (closed) and Phase 2 (open to enrollment)

Phase N/A

This is an open label, non-randomized, multi-center study. The primary purpose of the study is to evaluate the safety, tolerability and efficacy of Epacadostat and Durvalumab when given in combination in patients with Selected Advanced Solid Tumors.

Phase N/A

ImmuniCell in Patients With Advanced Cancers

This is an open-label trial of ImmuniCell® treatment of patients with malignant melanoma, renal cell cancer (RCC) or non-small cell lung cancer (NSCLC) which are refractory to current treatment or who have indolent disease for which immunotherapy may be beneficial. The trial is designed to identify a safe dose of ...

Phase

Study of rSIFN-co for Patients With Advanced Solid Tumors

The initial cohort will be 3 subjects. Escalation to the next dose will continue unless a subject experiences a DLT, at which time a cohort will be expanded to up to 6 subjects. Provided there is only one DLT in that cohort, the dose will be escalated. However, if there ...

Phase

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer

This study is a Phase 1 open-label, dose escalation, cohort expansion, and efficacy follow-up study of enoblituzumab administered intravenously (IV) on a weekly schedule for up to 51 doses in combination with IV pembrolizumab administered on an every-3-week schedule for up to 17 doses. The dose escalation phase is designed ...

Phase

Study of the CD40 Agonistic Monoclonal Antibody APX005M

APX005M-001 is an open-label study and comprises a dose-escalation portion of approximately 8 dose level cohorts, plus an expansion cohort. Eligible subjects with solid tumors will receive intravenous APX005M every 3 week, every 2 week or every 1 week until disease progression, unacceptable toxicity or death, whichever occurs first. Study ...

Phase

Study of MK-3475 in Conjunction With Lymphodepletion TIL and High or Low Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma

Study Groups: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 treatment groups (treatment arms): - If you are assigned to Arm A, you will receive high-dose IL-2. - If ...

Phase